Between 2007 and 2012, Kashiwagi et al. [16] published a series of papers which showed that S2R preferentially binds to pancreatic adenocarcinomas, and S2R ligands improved efficacy when combined with pancreatic cancer chemotherapeutic drugs [17,18]. The gene discussed is TMEM97; the disease is familial pancreatic carcinoma.